TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28089238

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg orally twice a day
Number of subjects: 41
Study: 28089456

Group type: EXPERIMENTAL
Intervention: 7 weeks of interval exercise training
Number of subjects: 16
Study: 28089618

Group type: EXPERIMENTAL
Intervention: Continuous (par)enteral nutrition with protein intake 1.0-3.7 g/kg/day
Number of subjects: 8
Study: 28089635

Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg recommended phase 2 dose) plus rituximab (375 mg/m2 monthly)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg) plus rituximab
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Venetoclax (50 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Venetoclax (20 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab
Number of subjects: 49
Study: 28089762

Group type: EXPERIMENTAL
Intervention: Concurrent weekly carboplatin and paclitaxel with 74 Gy of radiation in 37 fractions (2-Gy daily fractions)
Number of subjects: 25
Study: 28090295

Group type: EXPERIMENTAL
Intervention: Inhaled trepostinil
Number of subjects: 6
Study: 28090299

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg/day for the first 4 weeks, then 40 mg/day for the subsequent 20 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 12
Study: 28090332

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance <7% (Group A)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance ≥7% (Group B)
Number of subjects: 129
Study: 28090335

Group type: EXPERIMENTAL
Intervention: Top-down treatment with 5 Infliximab (IFX) infusions combined with azathioprine (AZA).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step-up treatment with standard induction treatment (oral prednisolone or exclusive enteral nutrition) combined with azathioprine (AZA) as maintenance treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step-up treatment
Number of subjects: 0
Study: 28090670

Group type: EXPERIMENTAL
Intervention: Nogo-B positive Kupffer cells in ALD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WT mice on Lieber-DeCarli ethanol liquid diet (5% ethanol) for 6 weeks
Number of subjects: 30
Study: 28091980

Group type: EXPERIMENTAL
Intervention: Tc-99m maraciclatide
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tc-99m sestamibi
Number of subjects: 39
Study: 28092464

Group type: EXPERIMENTAL
Intervention: Family support/behavior skills interest
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Discordance in parent/adolescent dyad responses
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Adolescent weight-loss goals
Number of subjects: 405
Study: 28093033

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28093823

Group type: EXPERIMENTAL
Intervention: Self-reported sleep
Number of subjects: 121
Study: 28094171

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT) for 12 weeks
Number of subjects: 63
Study: 28094314

Group type: EXPERIMENTAL
Intervention: High-dose intravenous (IV) esomeprazole for 72 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 72 hours
Number of subjects: 0
Study: 28095791

Group type: EXPERIMENTAL
Intervention: Person-centred and thriving-promoting intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inert control group
Number of subjects: 6
Study: 28095838

Group type: EXPERIMENTAL
Intervention: COMFORT intervention (family conversations led by a designated requester, separation of donation offer from end-of-life discussion, structured family donation conversation)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Pre-intervention usual practice
Number of subjects: 140
Study: 28096100

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 28096099

Group type: EXPERIMENTAL
Intervention: High-saturated-fat (HF) diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Carbohydrate-rich, low-fat diet
Number of subjects: 46
Study: 28096259

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mixed meal and infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lean control subjects
Number of subjects: 10
Study: 28096374

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0
Study: 28096387

Group type: EXPERIMENTAL
Intervention: GBT440
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AES103
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kinetic method
Number of subjects: 0
Study: 28096478

Group type: EXPERIMENTAL
Intervention: WEB device
Number of subjects: 150
Study: 28097013

Group type: EXPERIMENTAL
Intervention: Polyglucosamine (2 tablets x 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Orlistat (1 capsule x 3)
Number of subjects: 64
Study: 28097230

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28097231

Group type: EXPERIMENTAL
Intervention: Protein disulfide isomerase inhibition
Number of subjects: 0
Study: 28099715

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 28100190

Group type: EXPERIMENTAL
Intervention: Combined nutrition and resistance exercise intervention
Number of subjects: 25
Study: 28100441

Group type: EXPERIMENTAL
Intervention: Dot app (Dynamic Optimal Timing) for pregnancy prevention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1200
Study: 28100512

Group type: EXPERIMENTAL
Intervention: Fructose in mixed meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose in mixed meals
Number of subjects: 0
Study: 28100523

Group type: EXPERIMENTAL
Intervention: Preoperative RHI measurement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative L-arginine measurement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative ADMA measurement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative biopterin metabolites measurement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation between logAUC(l-arginine/ADMA) and logAUC(RHI)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation between logAUC(L-arginine/ADMA) and logAUC(BH4)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cardiac troponin I measurement
Number of subjects: 31
Study: 28100530

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 mcg/kg bolus for 10 minutes)
Number of subjects: 30
Study: 28100545

Group type: EXPERIMENTAL
Intervention: Chronic exposure to ambient air pollution (specific pollutants not detailed)
Number of subjects: 520
Study: 28100627

Group type: EXPERIMENTAL
Intervention: Growth/differentiation factor-15
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Adrenomedullin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Agouti-related protein
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Chitinase-3-like protein 1
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: C-C motif chemokine 20
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fatty acid-binding protein
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor receptor 1
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TNF-related apoptosis-inducing ligand
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biomarkers correlated with diastolic dysfunction (E/e')
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biomarkers correlated with left atrial volume index
Number of subjects: 86
Study: 28101105

Group type: EXPERIMENTAL
Intervention: Oral Administration of nan
Number of subjects: 0
Study: 28101354

Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 mg/m² or 25 mg/m²
Number of subjects: 1
Study: 28101959

Group type: EXPERIMENTAL
Intervention: Universal algorithm for rejection versus all nonrejection
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Selective algorithm for ABMR or TCMR
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Direct comparison of ABMR versus TCMR
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Union of top 200 transcripts from universal and selective algorithms
Number of subjects: 703
Study: 28103201

Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha therapy (Adalimumab, Infliximab, Etanercept)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha therapy (Adalimumab, Infliximab)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no anti-TNF alpha therapy)
Number of subjects: 38
Study: 28103715

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28103725

Group type: EXPERIMENTAL
Intervention: Bortezomib followed by romidepsin on days 1, 8, and 15
Number of subjects: 18
Study: 28103831

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for nAMD
Number of subjects: 5150

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for DME
Number of subjects: 5150

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for BRVO
Number of subjects: 5150

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for CRVO
Number of subjects: 5150

Group type: EXPERIMENTAL
Intervention: NIS OCEAN
Number of subjects: 5150
Study: 28103853

Group type: EXPERIMENTAL
Intervention: Aquatic Therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land-based Therapy
Number of subjects: 40
Study: 28103875

Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection (all infections)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection (sub-microscopic infections)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Sub-microscopic P. falciparum infections
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Increased UA resistance index
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Low cerebroplacental Doppler ratio
Number of subjects: 396
Study: 28103898

Group type: EXPERIMENTAL
Intervention: AL amyloidosis patients (n=341)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: AL amyloidosis patients with recently diagnosed disease and cardiac involvement
Number of subjects: 341
Study: 28104185

Group type: EXPERIMENTAL
Intervention: Causative pathogens identified in patients with sepsis
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: 28-day mortality in children
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: 28-day mortality in adults
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Severe sepsis on enrolment in children
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Severe sepsis on enrolment in adults
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Association of severe sepsis with mortality
Number of subjects: 1578
Study: 28104208

Group type: EXPERIMENTAL
Intervention: Polymer-free drug-filled stent (DFS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stent (historical control)
Number of subjects: 100
Study: 28104211

Group type: EXPERIMENTAL
Intervention: Balloon post-dilation (BPD)
Number of subjects: 3532

Group type: COMPARATOR
Intervention: No balloon post-dilation (Control)
Number of subjects: 3532
Study: 28104702

Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no IL-2 treatment)
Number of subjects: 100
Study: 28105667

Group type: EXPERIMENTAL
Intervention: Selective upper airway stimulation (sUAS)
Number of subjects: 20
Study: 28106016

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy in low-risk patients
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy in high-risk patients
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 6264
Study: 28106655

Group type: EXPERIMENTAL
Intervention: Transurethral polyacrylamide hydrogel injection
Number of subjects: 81
Study: 28107221

Group type: EXPERIMENTAL
Intervention: NAC + cash
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: NAC + food
Number of subjects: 805

Group type: COMPARATOR
Intervention: NAC-only
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: NAC + cash vs NAC + food
Number of subjects: 805
Study: 28107350

Group type: EXPERIMENTAL
Intervention: Institutional deliveries attended by skilled birth attendants
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Maternal mortality ratio
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Neonatal mortality ratio
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Perinatal mortality ratio
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 5469
Study: 28108386

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy and Amitriptyline (CBT+A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Headache Education and Amitriptyline (HE+A)
Number of subjects: 135
Study: 28108768

Group type: EXPERIMENTAL
Intervention: Severe hypercapnia developing within the first 48 hours after the start of mechanical ventilation
Number of subjects: 1899

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 1899
Study: 28109243

Group type: EXPERIMENTAL
Intervention: Neonatal hyperbilirubinemia treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants with neonatal hyperbilirubinemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infants without neonatal hyperbilirubinemia
Number of subjects: 0
Study: 28109259

Group type: EXPERIMENTAL
Intervention: Blood-pressure lowering agents and statins
Number of subjects: 1127

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1127
Study: 28109276

Group type: EXPERIMENTAL
Intervention: Microsystem model of care implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microsystem model of care
Number of subjects: 0
Study: 28109571

Group type: EXPERIMENTAL
Intervention: Stented gender-mismatched -80°C cryopreserved aortic allograft for airway reconstruction
Number of subjects: 2
Study: 28109895

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided HIFU treatment using volumetric shell ablation technique
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided HIFU treatment
Number of subjects: 73
Study: 28109951

Group type: EXPERIMENTAL
Intervention: Multimedia informed consent video and website incorporating cognitive strategies (15-min duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional informed consent process
Number of subjects: 0
Study: 28110120

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicarbonate dialysis (BHD)
Number of subjects: 0
Study: 28110346

Group type: EXPERIMENTAL
Intervention: Preoperative imaging and molecular biomarkers
Number of subjects: 109
Study: 28110770

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 118
Study: 28110982

Group type: EXPERIMENTAL
Intervention: MP-MRI
Number of subjects: 576

Group type: COMPARATOR
Intervention: TRUS-biopsy
Number of subjects: 576
Study: 28111758

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of 120 mmHg (intensive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systolic blood pressure target of 140 mmHg (standard)
Number of subjects: 0
Study: 28111925

Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab, irinotecan, and temozolomide (BIT)
Number of subjects: 33
Study: 28112798

Group type: EXPERIMENTAL
Intervention: Multidisciplinary perioperative protocol
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control (historical cohort)
Number of subjects: 600
Study: 28113028

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28114316

Group type: EXPERIMENTAL
Intervention: Maternal conditional weight gain (CWG) in the first window (≤ 20 weeks)
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Maternal conditional weight gain (CWG) in the second window (21-29 weeks)
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Maternal conditional weight gain (CWG) in the third window (≥ 30 weeks)
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Women gaining below the Institute of Medicine guidelines
Number of subjects: 1436
Study: 28114441

Group type: EXPERIMENTAL
Intervention: Higher-risk group (41 participants)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lower-risk group (59 participants)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall group comparison (higher-risk vs lower-risk women)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall group (65 women)
Number of subjects: 100
Study: 28114554

Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 879

Group type: COMPARATOR
Intervention: SIRS
Number of subjects: 879

Group type: COMPARATOR
Intervention: severe sepsis
Number of subjects: 879
Study: 28114604

Group type: EXPERIMENTAL
Intervention: Imiquimod cream, 5% applied topically once per day for 4 consecutive days on specified cycles for 12 weeks, combined with albumin bound paclitaxel, 100 mg/m2 intravenously on days 1, 8, and 15, repeated every 28 days for 12 weeks
Number of subjects: 15
Study: 28114884

Group type: EXPERIMENTAL
Intervention: Maternal vascular endothelial growth factor (VEGF) gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised longitudinal ultrasound measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical markers from maternal blood samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counselling for couples with affected pregnancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bio-banking of maternal blood, urine, amniotic fluid, placenta, umbilical cord blood, and placental bed samples
Number of subjects: 0
Study: 28114898

Group type: EXPERIMENTAL
Intervention: Initial empirical antifungal therapy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Initial pre-emptive antifungal therapy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Initial targeted antifungal therapy
Number of subjects: 306
Study: 28114962

Group type: EXPERIMENTAL
Intervention: COPE intervention (Caregivers of cancer Outpatients' Psycho-Education support group therapy), comprising four weekly sessions targeting psychoeducation, skills training, and supportive therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPE intervention
Number of subjects: 0
Study: 28115071

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) supported employment for 24 months
Number of subjects: 213
Study: 28115490

Group type: EXPERIMENTAL
Intervention: Long noncoding RNAs (lncRNAs) differentially expressed after ischemia in the human heart.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long noncoding RNAs (lncRNAs) identified through RNA sequencing.
Number of subjects: 0
Study: 28115515

Group type: EXPERIMENTAL
Intervention: Prematurely born children
Number of subjects: 180

Group type: COMPARATOR
Intervention: Healthy controls born at term
Number of subjects: 180
Study: 28115916

Group type: EXPERIMENTAL
Intervention: Exercise testing in patients with CAD
Number of subjects: 106

Group type: COMPARATOR
Intervention: Exercise testing in patients without CAD
Number of subjects: 106
Study: 28116120

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness-based intervention delivered via Skype group videoconferences
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 60
Study: 28116164

Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise program (intermittent walking to mild-to-moderate claudication pain for three months)
Number of subjects: 48
Study: 28116294

Group type: EXPERIMENTAL
Intervention: Nine different pulse contour algorithms
Number of subjects: 0
Study: 28116335

Group type: EXPERIMENTAL
Intervention: Pseudophakic monovision correction (MoG)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Multifocal lens implantation (MfG)
Number of subjects: 122
Study: 28116595

Group type: EXPERIMENTAL
Intervention: Early fluid administration (total fluid infused in the first 6 hours)
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: Shock status
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: Pneumonia as a site of infection
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: Pancreatitis
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: Acute abdomen
Number of subjects: 2534
Study: 28117498

Group type: EXPERIMENTAL
Intervention: Insomnia (measured using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Anxiety, type of treatment, back muscle strength, pain severity, and stage of treatment
Number of subjects: 123
Study: 28117556

Group type: EXPERIMENTAL
Intervention: Overfeeding for 8 weeks
Number of subjects: 14
Study: 28117906

Group type: EXPERIMENTAL
Intervention: Integrative Cognitive-Affective Therapy (ICAT-BN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy-Enhanced (CBT-E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both ICAT-BN and CBT-E
Number of subjects: 80
Study: 28118536

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 17

Group type: COMPARATOR
Intervention: Anakinra vs Canakinumab
Number of subjects: 17
Study: 28118823

Group type: EXPERIMENTAL
Intervention: Civic engagement intervention through Change Clubs
Number of subjects: 28
Study: 28119279

Group type: EXPERIMENTAL
Intervention: Cognitive nonaction video games (Lumosity)
Number of subjects: 75

Group type: COMPARATOR
Intervention: The Sims and SimCity (active control)
Number of subjects: 75
Study: 28119295

Group type: EXPERIMENTAL
Intervention: Margetuximab (0.1-6.0 mg/kg for Regimen A, 10-18 mg/kg for Regimen B) administered by intravenous infusion, 3 of every 4 weeks for Regimen A or once every 3 weeks for Regimen B.
Number of subjects: 66
Study: 28119352

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97
Study: 28119390

Group type: EXPERIMENTAL
Intervention: mHealth and home-monitoring systems for asthma management
Number of subjects: 150